Overcoming Adaptive Resistance to KRAS and MEK Inhibitors by Co-targeting mTORC1/2 Complexes in Pancreatic Cancer

著者: Wells S. Brown, Paul C. McDonald, Oksana Nemirovsky, Shannon Awrey, Shawn C. Chafe, David F. Schaeffer, Jinyang Li, Daniel J. Renouf, Ben Z. Stanger, Shoukat Dedhar - Cell Reports Medicine 2020 被引用: 108

and increased survival. We have identified an effective combinatorial treatment strategy using clinically viable inhibitors, which can be applied to PDAC tumors with different KRAS mutations.